Full Press Release Details
Accessibility: Skip TopNav
Summit Corporation PLC : Application to Trading
April 23, 2012 06:30 ET
Summit Therapeutics plc
Summit Therapeutics plc
Summit Corporation plc
('Summit' or 'the Company')
APPLICATION TO TRADING
Oxford, UK, 23 April 2012, Summit (AIM: SUMM), a UK drug discovery company, announces that, further to the passing of the resolutions at the General Meeting of the Company on 20 April 2012, application has been made for 166,666,670 new Ordinary Shares to be admitted to trading on the AIM market of the London Stock Exchange. Admission to trading is expected to take place at 8.00 a.m. on 24 April 2012.
Following admission, the Company will have 354,088,450 Ordinary Shares in issue.
For more information, please contact:
| Summit Glyn Edwards / Richard Pye | Tel: +44 (0)1235 443 939 |
| Singer Capital Markets (Nominated Adviser and Joint broker) Shaun Dobson / Claes Spång | Tel: +44 (0)203 205 7500 |
| Hybridan LLP (Joint broker) Claire Louise Noyce / Deepak Reddy | Tel: +44 (0)207 947 4350 |
| Peckwater PR (Financial public relations) Tarquin Edwards | Tel: +44 (0)7879 458 364 tarquin.edwards@peckwaterpr.co.uk |
Summit is an Oxford, UK based drug discovery Company with an innovative Seglin(TM) technology platform for the discovery of new medicines and a portfolio of drug programme assets. Summit's programme portfolio consists of a number of drug programmes targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection. Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com.